# Wuhan HealthCare Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/wuhan-healthcare-biotechnology-co

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.healthcare-bio.com
- Total disclosed funding: $4.5M
- Latest round: Series C (Jul 29, 2021)
- Investors on record: 7

## About

Based in Wuhan, China and established in 2013, Wuhan HealthCare Biotechnology Co., Ltd. is a medical service provider that provides clinical diagnosis of major diseases for clinical hospitals and third-party independent clinical testing institutions and guide clinical drug molecular diagnostic products and clinical molecular diagnostic programs. The company cooperated with pathology Branch of China Medical Equipment Association to set up a training base, and also cooperated with Peking Union Medical College Hospital, Peking University Cancer Hospital and other hospitals. From 2015 to 2021, Wuhan HealthCare Biotechnology Co., Ltd. closed different rounds of venture funding from multiple investors including YuanBio Venture, Sinopharm Capital, Hubei High Technology, Yanghe Biomedicine Industry Investment, Chuchang Fund and Luojia Capital. In August 2025, Shanghai Tellgen Life Science announced to acquire majority stake in Wuhan HealthCare Biotechnology Co., Ltd. for CNY 291.45 million from the company's existing shareholders including the preceding-mentioned investors, marking their full exit from the company.

The company mainly provides molecular diagnostic equipment and testing services, including rapid fluorescence in situ hybridization probes, pharmacogenomics detection reagents and fluorescence in situ hybridization equipment. Its self-developed FastProbe® fluorescence in situ hybridization probe preparation technology shortens the detection time of fluorescence in situ hybridization from 3 days to several hours, and has higher sensitivity, specificity and bright signal-to-noise ratio. The company's products are mainly used in major diseases such as cardiovascular, cerebrovascular, tumor, cancer, etc. The company is promoting the implementation of two automated testing equipment in the field of solid tumors and hematological tumors, and it is expected to be put on the market in the second half of 2021 at the earliest.

## Funding rounds

- Series C, Jul 29, 2021 — Hubei High Technology, Luojia Capital, Chuchang Fund
- Series B, Mar 20, 2019 — Shanghai Jianyi Private Equity Fund Management
- Series A, Nov 7, 2017, $4.5M — YuanBio Venture
- Angel, Sep 10, 2015 — China Financial Innovation Investment, Yanghe Biomedicine Industry Investment

## Investors

- China Financial Innovation Investment (https://capitalatlas.ai/funds/china-financial-innovation-investment) — Angel
- Yanghe Biomedicine Industry Investment (https://capitalatlas.ai/funds/yanghe-biomedicine-industry-investment) — Angel
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series B
- Hubei High Technology (https://capitalatlas.ai/funds/hubei-high-technology) — Series C
- Luojia Capital (https://capitalatlas.ai/funds/luojia-capital) — Series C
- Chuchang Fund (https://capitalatlas.ai/funds/chuchang-fund) — Series C